Loading…
Loading…
KNBIF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for KNBIF and 80,000+ other tickers.
See exactly how KNBIF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for KNBIF and 80,000+ other tickers.
Kane Biotech Inc. is a biotechnology firm specializing in the research, development, and global commercialization of innovative technologies and products focused on preventing and eradicating microbial biofilms. The company's diverse product lineup includes pet dental care solutions under the StrixNB and bluestem brands, as well as DispersinB for treating wounds in both animals and humans. They also manufacture Alosera shampoos for dogs, cats, and horses, and Aledex coatings for medical devices. Additionally, Kane Biotech provides DermaKB products for scalp health, Coactiv+ for wound…
DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth initiatives DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth initiatives
WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.
Kane Biotech Inc. (KNE:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 29, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that on May 28, 2026 it granted an aggregate of 9,750,000 stock options (the "Options") to certain directors, officers, employees and consultants of the Company in accordance with the Company's third amended and restated stock option plan. Each Option is exercisable into one common share of the Company (a “Share”) at a price of $0.05 per Share, for a period of five years from the date of grant.
WINNIPEG, Manitoba, May 28, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its first quarter 2026 financial results.